Colossal Biosciences is a de-extinction and species preservation company that has raised over $485 million to resurrect species like the woolly mammoth, dire wolf, and thylacine.
The company has achieved significant technological breakthroughs, including the ability to make over 50 simultaneous genetic edits in a single cell line and successfully cloning endangered red wolves.
Colossal employs a dual business model, monetizing through long-term ecosystem restoration projects funded by nature credits and ecotourism, while also spinning out valuable technologies for human healthcare and industrial applications.
The core process involves sequencing ancient DNA, using computational biology to identify key genes, editing the genome of a close living relative, and developing novel reproductive technologies like artificial wombs to bring the proxy species to term.
10 quotes
Concerns Raised
Technical difficulty in achieving high-efficiency multiplex editing and DNA delivery
Challenges in developing novel reproductive technologies like artificial wombs and universal eggs
Navigating the complex and slow-moving FDA regulatory framework for gene-edited animals
Public perception and ethical concerns around 'playing God' and genetic engineering
Opportunities Identified
Spinning out valuable platform technologies for human healthcare and industrial applications
Monetizing large-scale rewilding projects through biodiversity and carbon credits
Creating a 'free R&D arm' for the underfunded conservation community
Becoming the global leader in advanced cloning, gene editing, and reproductive technologies